VENTRIX INCORPORATED
San Diego, CA · Founded 2009 · CIK 0001496821 · Medtech · Private
Injectable hydrogel biomaterials derived from decellularized extracellular matrix for cardiac repair and heart failure treatment
ventrix.com.br →- Grants
- $5.2M
- 6 awards
- Sector median: 1
- Raised
- $5.2M
- 2 Form D · May 2012
- 172 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $80,000 | |
| Private capital raised | Form D · SEC | $5,163,118 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase IIB: Percutaneous deliverable biomaterial for treating myocardial infarction | $1,026,130 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · New infusible ECM hydrogel for treating acute myocardial infarction | $791,543 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · New infusible ECM hydrogel for treating acute myocardial infarction | $791,543 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI | $552,109 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI | $552,109 | |
| Federal grant | Department of Health and Human Services · Phase II · Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI | $1,440,231 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 930 | NeuroSigma, Inc. | — | $13M |
| 931 | CymoGen Dx, LLC | — | $350K |
| 932 | ADVANCED BIODEVICES LLC | — | — |
| 933 | VENTRIX INCORPORATED | — | $5.2M |
| 934 | Long Bridge Medical, Inc. | — | $7.2M |
| 935 | Medical Care Technologies Inc. | — | $50K |
| 936 | Endoshape, Inc. | — | $23M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Karen ChristmanDirector
- Adam KinseyDirector · Executive Officer · Promoter
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.